Autism Spectrum Disorder Trial, Recruiting NCT06868537 Sponsor: The University of Texas Health Science Center, Houston Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06868537
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The person has been diagnosed with Autism Spectrum Disorder (ASD) by a licensed mental health or medical professional
  • A parent has completed a specific communication and social skills questionnaire (called the SCQ-L), and the score is above 14
  • The person meets the standard diagnostic guidelines for ASD (known as DSM-5 criteria), based on a symptom checklist
  • The person is willing and motivated to take part in the treatment program
  • A parent or caregiver is willing to take part alongside the person
  • The person has a verbal thinking and language ability score above 70, as measured by a specific intelligence test (called the KBIT-2-R)

Who may not be able to join:

  • People who have a history of a psychotic disorder, or who are currently experiencing psychotic symptoms
  • People who are currently having thoughts of suicide with a plan or intention to act on them
  • People who currently have a severe alcohol or other substance use disorder
  • People who are currently enrolled in another clinical trial specifically for autism spectrum disorder
  • People who express that they are unwilling to complete the study's required procedures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antonio Pagan, PhD, The University of Texas Health Science Center, Houston

Phone: (713) 486-2700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 July 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in adaptive functioning as assessed by the Adaptive Behavior Assessment System, Third Edition (ABAS-3); Change in social response as assessed by the Social Responsiveness Scale, Second Edition (SRS-2); Change in transition readiness as assessed by the Transition Readiness Scale (TRS)-child version; Change in transition readiness as assessed by the Transition Readiness Scale (TRS)-parent version

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov